Thu, Sep 18, 2014, 10:22 AM EDT - U.S. Markets close in 5 hrs 38 mins


% | $
Quotes you view appear here for quick access.

Celator Pharmaceuticals, Inc. Message Board

  • mghmd mghmd Jan 13, 2014 10:59 AM Flag

    The case for CPX-351

    In multiple phase2 studies, CPX-351, an emulsified preparation of daunorubicin and cytosine arabinoside in a 5:1 fixed molar concentration, has shown superiority over conventional daunorubicin and cytosine arabinoside(3 + 7) in the Rx of adults with AML. This superiority is even more pronounced in patients with secondary AML(AML following chemotherapy for solid malignancies, AML evolving out of myelodysplastic syndrome). Hence, for its ph3 FDA study, the company wisely selected the more limited indication of secondary AML; the chances of success in secondary AML based on prior experience seems excellent. Assuming success with ph3, the company will have a long time window under its orphan drug status to get the drug approved for conventional AML. Studies are also underway in pediatric AML and adult myelodysplastic syndrome. A potential big market for a company with a tiny market cap.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.79-0.03(-1.06%)Sep 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.